Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open
News Summary
Gilead Sciences, Inc. (GILD) saw strong after-hours activity on Friday, December 19, 2025, driven by two key catalysts: a new U.S. government pricing agreement related to TrumpRx and tariff relief, and fresh U.K. regulatory approval for lenacapavir. The stock closed up 2.32% in the regular session and remained constructive after hours. The TrumpRx deal is a three-year agreement involving
Background
Gilead Sciences, Inc. is a leading global biopharmaceutical company, with core competencies particularly in HIV and liver disease treatments (such as hepatitis C and B). Its product portfolio includes blockbuster drugs like Biktarvy, Descovy, and Epclusa, while lenacapavir is a significant strategic product in its HIV prevention pipeline. The administration of Donald J. Trump (re-elected in November 2024) has prioritized reducing drug prices as a key domestic policy. The TrumpRx.gov platform and
In-Depth AI Insights
Is the Trump administration's drug pricing strategy genuinely aimed at cost reduction, or is it primarily political theater? What are the long-term implications? - The market's reaction to Gilead's stock suggests investors perceive these agreements more as a reduction in policy tail-risk (especially tariffs) rather than a material hit to cash flow. This may imply that the